NCT01066611View on ClinicalTrials.gov

Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions
Allergic Rhinitis
Interventions
DRUG

CAL-263

CAL-263 10 mg or placebo once daily for 7 days

DRUG

Placebo

CAL-263 10 mg or placebo once daily for 7 days

Trial Locations (1)

Unknown

Vienna Challenge Chamber, Vienna

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY